NMN (β-Nicotinamide Mononucleotide)
NMN (β-nicotinamide mononucleotide) is a nucleotide the body uses to make NAD+, a coenzyme every cell needs for energy-producing reactions. The regulatory picture comes first here, because it governs what can and cannot be said about NMN: in Great Britain the FSA classifies NMN as a novel food that is not yet authorised, and there are no authorised UK health claims for it. In the EU, EFSA adopted a positive safety opinion in 2026 — judging up to 300 mg/day safe for adults other than during pregnancy and lactation, and assessing how well the body absorbs nicotinamide from NMN — but that is a safety and bioavailability opinion, not proof that NMN slows ageing or extends lifespan, and an EU authorisation decision is still pending. Beneath that authoritative guidance, our own reading of the trials is cautious: most of the lifespan and rejuvenation framing online sits well ahead of the human evidence.
Camden Medicals editorial · Last reviewed 11 June 2026 · Next review September 2026
- Cross-checked against
- NHS
- NICE
- BNF
- EFSA
- FSA
Camden's editorial team independently graded each health claim below on the strength of the published evidence — see the grade beside every condition.
- Class
- Nucleotide
- Typical daily dose
- UK retail products supply NMN at 125–1,000 mg/day. Trials reporting NAD+ marker rise have used 250–1,000 mg/day for 4–12 weeks. There is no UK consensus dose because there is no authorised UK health claim. Dose ranges are descriptive of trial conditions only.
- Top use evidence
- Limited
On this page
What it is
β-Nicotinamide mononucleotide (NMN) is a nucleotide consisting of nicotinamide attached to a ribose-phosphate group. The body synthesises it from nicotinamide (a B3 vitamer) and uses it as the immediate precursor to NAD+ — nicotinamide adenine dinucleotide — the redox cofactor used by every cell in energy-producing reactions including glycolysis, the citric-acid cycle, and oxidative phosphorylation.
NMN was popularised as a food supplement after work in the Sinclair laboratory at Harvard (and others) reported that aged mice fed NMN showed rises in tissue NAD+ and metabolic improvements. The translation to human use is partial — small short trials in adults have reported rises in blood NAD+ markers after 4–12 weeks of NMN supplementation, but clinical-outcome trials (lifespan, age-related disease, frailty) in humans do not exist at the time of writing.
Modern food-supplement preparations supply NMN as a stable crystalline powder, usually in capsules, sometimes with a delayed-release shell to spare the upper GI tract. Doses in UK retail run 250–1000 mg/day. The most-cited mechanistic pairing is with trimethylglycine (TMG, betaine) — methyl-group donor — because NMN clearance via NNMT consumes methyl groups from the SAM (S-adenosyl methionine) pool.
Regulatory note (the authoritative position leads; see the guidance block for sourced summaries): in Great Britain the FSA classifies NMN as a novel food. NMN does not have a documented history of significant consumption before 15 May 1997, so under assimilated Regulation (EU) 2015/2283 it requires authorisation; it is not on the GB authorisations register, and a GB determination has not been made. Products linked to an in-process application may remain on the market under the transitional arrangements while that decision is pending. In the EU the picture moved in 2026: EFSA's NDA Panel adopted a positive safety opinion on an applicant's β-NMN (EFSA Journal DOI 10.2903/j.efsa.2026.10007), concluding that up to 300 mg/day is safe for the general adult population — excluding pregnant and lactating women — as a source of niacin, and assessing the bioavailability of nicotinamide from NMN. That is a safety and bioavailability opinion, not an efficacy or health-claim endorsement, it did not evaluate intakes above 300 mg/day, and a European Commission authorisation decision is still pending. The US pathway is separate: the FDA confirmed NMN lawful in US dietary supplements in September 2025, with further New Dietary Ingredient (NDI) status letters in December 2025, after the 2022 dispute — a US position only. NR (nicotinamide riboside), a closely related NAD precursor, is GB-authorised as a novel food via a separate authorisation; NR and NMN are not interchangeable as products from a regulatory standpoint.
At a glance
- A naturally occurring nucleotide that the body uses to make NAD+ (a coenzyme central to energy-producing reactions in every cell).
- No UK-authorised food-supplement health claims for NMN. Rejuvenation, lifespan-extension, mitochondrial-function, energy and NMN→NAD+ effect claims are not permissible on any Camden surface.
- Regulatory position (the primary anchor): in Great Britain the FSA classifies NMN as a novel food that is not yet authorised. In the EU, EFSA adopted a positive safety opinion in 2026 (up to 300 mg/day judged safe for adults, excluding pregnancy and lactation) — a safety and bioavailability opinion only, with EU authorisation still pending. None of this creates an authorised UK health claim or an efficacy claim of any kind.
- Most NMN human trials are small (n < 100), short (8–12 weeks), and report blood-NAD-marker rises rather than clinical outcomes. Lifespan-extension outcome trials in humans do not exist at the time of writing.
- NMN clearance consumes methyl groups; products often pair NMN with TMG (trimethylglycine) for that reason. The pairing is mechanistic, not claim-supported.
What people use it for
Adults curious about NAD precursor supplementation, with awareness of regulatory and evidence limits
Small short trials of NMN 250–1,000 mg/day across 8–12 weeks have reported rises in blood NAD+ markers (whole-blood, peripheral mononuclear cell). Clinical-outcome trials in humans do not exist. UK food-supplement claims for NMN are not permitted; NMN sits on the FSA novel-food register as "pending".
Some evidenceLimitedAdults considering NMN for diagnosed age-related conditions, frailty, or specific clinical disease
NMN is not a UK-recognised pathway for any of these uses. UK NHS / NICE pathways apply for the underlying conditions. Self-supplementation with a food supplement under novel-food assessment is not the appropriate pathway for diagnosed disease.
Popular, not provenInsufficientAdults exploring rejuvenation or lifespan-extension supplementation
There are no human lifespan-outcome trials for NMN. The animal literature is older and partly contested. UK food-supplement claims for rejuvenation or lifespan-extension are not permitted. The framing should be exploratory, not therapeutic.
Popular, not provenInsufficientAdults already supplementing NMN and interested in methyl-pool support
NMN clearance via NNMT consumes methyl groups from the SAM pool. Pairing NMN with TMG (trimethylglycine) supplies a direct methyl-group donor that regenerates methionine from homocysteine. The pairing is widely used for this mechanistic reason; outcome trials of the combination as such are limited. Camden NB-161 is formulated with both.
Some evidenceLimited
How it works
NMN is converted to NAD+ via the NMNAT enzymes in cells. NAD+ is the redox cofactor that accepts and donates electrons in energy-yielding reactions — making the cell-energy framing biochemically accurate but not clinically claim-substantiated for food-supplement NMN at the doses used in retail products.
Common myths
Myth"NMN reverses ageing or extends human lifespan"
RealityThere are no human lifespan-outcome trials for NMN. The animal-data framing has not been translated to humans, and the popular age-reversal framing is marketing, not clinical evidence. UK food-supplement health claims for lifespan or rejuvenation are not permitted on NMN.
Myth"NMN raises NAD+ — therefore NMN reverses age-related disease"
RealityBlood NAD+ marker rise is not the same as clinical-outcome improvement. The trial endpoints are different. Marker rise without clinical outcome is the most common finding in NMN trials; using marker rise to imply disease modification is not a regulator-permissible claim.
Myth"NMN is the same as nicotinamide riboside (NR)"
RealityBiochemically related, regulatorily distinct. NR is GB-authorised as a novel food. NMN is not yet authorised in GB (EFSA gave a positive EU safety opinion in 2026, but GB authorisation has not been granted). Health-claim wording permissible on one is not permissible on the other; product substitution between them is not a like-for-like replacement from a regulatory standpoint.
Myth"NMN works because the FDA approved it, or because EFSA said it is safe"
RealityRegulatory acceptance is not the same as clinical benefit. The US FDA confirmed NMN lawful in dietary supplements in 2025 — a US market position only. EFSA's 2026 opinion found an applicant's β-NMN safe at up to 300 mg/day for adults (excluding pregnancy and lactation) and assessed how nicotinamide is absorbed from it — that is a safety and bioavailability judgement, not evidence that NMN slows ageing or improves health. In Great Britain NMN is not yet authorised, and no regulator has approved any health claim for NMN anywhere.
Myth"NMN is safe at any dose because it's natural"
RealityLong-term safety in humans (>12 months) is not established. The trials that exist are short (4–12 weeks) and small (n < 100). The "natural-therefore-safe" framing does not substitute for safety data; it is one of the headline cautions the FSA and EFSA assessment processes are evaluating.
Common online questions
Synthesised from the questions UK shoppers most often ask online about NMN (β-Nicotinamide Mononucleotide). Each answer is editorial and links to its evidence in the Sources list below.
What is the UK and EU regulatory status of NMN?
NMN does not have a documented history of significant consumption before 15 May 1997, so it is treated as a novel food that needs authorisation. In Great Britain the FSA has not authorised NMN — it is not on the GB authorisations register, and a determination has not been made; products linked to an in-process application may remain on the market under the transitional arrangements while that decision is pending. In the EU the position moved in 2026: EFSA's expert panel adopted a positive safety opinion on an applicant's β-NMN, judging up to 300 mg/day safe for adults other than during pregnancy and lactation and looking at how well nicotinamide is absorbed from it. That opinion is about safety, not about proving a benefit, and a European Commission authorisation decision is still pending. Whatever happens, no health claim is permitted on NMN in the UK. Camden Medicals stocks NMN under transparent disclosure of this status; the position is moving and is tracked on the encyclopaedia review schedule.
Will NMN make me "feel younger" or extend my lifespan?
There are no human lifespan-outcome trials for NMN. Most of the popular framing extrapolates from animal data, which is older, partly contested, and has not been translated into human clinical outcomes. UK food-supplement claims for rejuvenation or lifespan-extension are not permitted on NMN. If you choose to supplement, the realistic framing is exploratory: NAD+ markers may rise; clinical impact is not established.
NMN vs NR (nicotinamide riboside) — is one better?
NR (nicotinamide riboside) is GB-authorised as a novel food via a separate authorisation. NMN is on the novel-food register as "pending" — under assessment. The two molecules are closely related precursors to NAD+ and the in-vivo endpoints (blood NAD+ rise) are similar in magnitude across the small trials of each. From a UK regulatory standpoint they are not interchangeable as products, even though the biochemistry is closely related. Neither has authorised UK food-supplement health claims.
Why is TMG (trimethylglycine) usually paired with NMN?
NMN is converted to NAD+, which is then consumed and ultimately cleared back to nicotinamide. The clearance step via nicotinamide N-methyltransferase (NNMT) uses a methyl group from S-adenosyl methionine (SAM). High NAD+ flux therefore depletes the methyl pool. TMG (betaine) is a direct methyl-group donor that regenerates methionine from homocysteine, buffering the methyl pool. The pairing is mechanistic; outcome-trial evidence for the combination as such is limited. Camden NB-161 includes both at the commonly-cited literature ratio (500 mg NMN + 600 mg TMG).
Can I take NMN if I am pregnant, breastfeeding, or trying to conceive?
No. NMN has not been studied in pregnancy or lactation, sits on the novel-food register as "pending" (no authorised UK consumption history), and includes no human safety data in these populations. Avoid in pregnancy and lactation. If you are trying to conceive, talk to your GP before supplementing.
Should I take NMN if I have a diagnosed cancer or am on cancer treatment?
Talk to the team managing your care first. NAD+ metabolism is relevant in cancer biology; NMN supplementation in active oncology should not be self-initiated. The conservative position in the absence of clinical-trial data is to defer to your oncology team.
Camden guides citing NMN (β-Nicotinamide Mononucleotide)
Editorial pieces from the Camden blog that reference NMN (β-Nicotinamide Mononucleotide). Each guide cites the evidence it draws on.
🔬 Camden’s evidence review
The research Camden reviewed, graded on its strength. This is our own appraisal — it sits beneath the official guidance above, never above it.
Blood NAD+ marker rise — short-term supplementation
LimitedEvidencelimitedAuthoritative position first: no UK or EU body has assessed NMN for this or any efficacy endpoint; EFSA's 2026 opinion addressed safety and nicotinamide bioavailability only. Camden's reading of the research: small short trials of NMN 250–1,000 mg/day across 4–12 weeks have reported rises in whole-blood NAD+ and peripheral-blood mononuclear-cell NAD+. Trials are small (n < 100), funded by the supplement industry in most cases, and report a marker rise rather than a clinical-outcome change. Independent large-scale replication is limited.
Clinical age-related outcomes (frailty, sarcopenia, cognition, lifespan)
InsufficientEvidenceinsufficientAuthoritative position first: there is no UK/EU guideline or regulator position supporting NMN for any age-related outcome, and NHS pathways for the underlying conditions are the recognised route. Camden's reading of the research: human clinical-outcome trials of NMN supplementation in ageing or age-related disease are not established at the time of writing. The popular framing rests on animal data that has not been translated into human outcome trials.
Cardiometabolic markers — short-term
InsufficientEvidenceinsufficientAuthoritative position first: no UK/EU body has assessed NMN for cardiometabolic benefit, and no such claim is authorised on UK food-supplement labels. Camden's reading of the research: some small trials have reported changes in markers like insulin sensitivity in specific subpopulations, but trial sizes and durations are inadequate for clinical conclusions.
Safety in healthy adults — short-term
LimitedEvidencelimitedAuthoritative position first: EFSA's 2026 safety opinion judged up to 300 mg/day safe for the general adult population, excluding pregnant and lactating women, and did not assess higher intakes; the NHS notes that 500 mg/day or less of nicotinamide from supplements is unlikely to cause harm. Camden's reading of the research: short trials in healthy adults have reported NMN 250–1,000 mg/day to be generally well-tolerated, with most adverse events mild and GI in nature. Long-term safety in humans (>12 months) is not established.
Safety
EFSA's 2026 safety opinion judged up to 300 mg/day of NMN safe for the general adult population, excluding pregnancy and lactation, and did not assess higher intakes; short trials report NMN to be generally well-tolerated, mostly with mild gastrointestinal effects. Long-term human safety (>12 months) is not established. In Great Britain NMN is a novel food that is not yet authorised, and no health claims are permitted. Pregnancy, lactation, under-18s, and active cancer treatment: avoid, or defer to your care team.
Talk to your pharmacist or GP first if you:
- You are pregnant, breastfeeding, or trying to conceive.
- You are under 18.
- You have a diagnosed cancer or are on cancer treatment — defer to your oncology team.
- You take immunosuppressants, mTOR inhibitors, or are post-transplant.
- You have liver or kidney disease.
- You take any prescribed medication and are unsure of NAD-pathway interactions — disclose supplement use to your prescriber.
Common side effects: Mild GI complaints (nausea, abdominal discomfort, loose stools) — particularly at higher doses or without food. Headache and flushing are uncommonly reported.
Pregnancy and breastfeeding
No human pregnancy safety data. NMN is on the FSA novel-food register as "pending"; the absence of authorised consumption history compounds the absence of pregnancy data. Avoid.
No human lactation safety data. Avoid.
Talk to your GP, midwife, or pharmacist before starting any supplement during pregnancy or breastfeeding.
More clinical detail (for clinicians and informed readers)
Contraindications
- Pregnancy and lactation — avoid (no human safety data; novel-food status pending).
- Paediatric use — avoid.
- Active cancer or cancer treatment — defer to oncology team given NAD+ metabolism in tumour biology.
Drug interactions
- Immunosuppressants and mTOR inhibitors — theoretical interaction via shared metabolic pathways; defer to prescriber.
- Anti-cancer therapy — theoretical interaction; defer to oncology team.
- No well-characterised pharmacokinetic interactions with common prescription medication at trial doses, but the interaction literature is sparse.
This is not an exhaustive list. Always tell your prescriber and pharmacist about every supplement you take.
Common side effects
- Mild GI complaints — nausea, abdominal discomfort, loose stools; substantially reduced by taking with food.
Rare side effects
- Headache, flushing.
- Idiosyncratic allergic reaction.
- Insomnia at high evening doses (anecdotal; not a defined trial endpoint).
How to take it
- Typical supplemental range
- UK retail products supply NMN at 125–1,000 mg/day. Trials reporting NAD+ marker rise have used 250–1,000 mg/day for 4–12 weeks. There is no UK consensus dose because there is no authorised UK health claim. Dose ranges are descriptive of trial conditions only.
- Timing
- Daily, with food. NMN itself is acid-labile; delayed-release shells are common to spare the upper GI tract. Effects on blood NAD+ markers are reported across 4–12 weeks; acute / single-dose effects are not the trial endpoint.
How to spot quality
Look for
- β-NMN explicitly stated (β-isomer is the bioactive form; α-isomer is inactive).
- Purity declared (typically ≥99% by HPLC).
- Country of manufacture stated and CoA available on request.
- Heavy-metal screening disclosed.
- Delayed-release or enteric-coated capsule for upper-GI sparing.
- TMG (trimethylglycine) included or recommended for methyl-pool support — mechanistic pairing.
- Transparent FSA novel-food assessment disclosure on the PDP — products remain available during the assessment window, but claims are not permitted.
- No rejuvenation, lifespan-extension, NMN→NAD+, mitochondrial-function, or cellular-youth claims — those are not permitted on UK food supplements.
Red flags
- No β-isomer declaration.
- No purity / CoA disclosure.
- Rejuvenation, lifespan-extension, age-reversal, biological-age-reversal, or NAD-pathway raising framing on the label or PDP.
- Comparisons to NR or vitamin B3 implying interchangeability.
- Claims that NMN remedies or addresses specific age-related conditions (frailty, sarcopenia, dementia).
- Implication that the FDA NDI restoration constitutes a UK health-claim authorisation.
- No FSA novel-food disclosure on the PDP.
Where Camden lands · meets the bar
Camden has one NMN-bearing SKU — NB-161 NMN Complex 90 Delayed Release Capsules. It supplies 500 mg β-NMN per capsule alongside 600 mg TMG (methyl-pool support), 300 mg quercetin, 170 mg trans-resveratrol, 100 mg pterostilbene, and 150 µg vitamin B12 (6,000% NRV). The capsule uses an HPMC delayed-release shell to spare the upper GI tract. Camden makes no health claims on NMN itself — the regulatory anchor for fatigue / energy / cognition framing on the NB-161 PDP is on vitamin B12, which carries EFSA-permitted claims, not on NMN. In Great Britain NMN is a novel food that is not yet authorised; Camden ships it under transparent disclosure of that status. Note for review: EFSA's 2026 safety opinion considered up to 300 mg/day safe for adults and did not assess higher intakes, whereas NB-161 supplies 500 mg β-NMN per capsule — a point Camden surfaces honestly and an open item flagged to the pharmacist/operator for a commercial decision.
Commonly combined with
Other ingredients that share a biological pathway, cofactor relationship, or evidence-backed protocol with this one. Mechanisms below cite primary physiology — not folk pairing. Doses are literature ranges, not recommendations. Talk to your pharmacist or GP before changing your stack, especially if you take prescription medication.
Trimethylglycine (TMG / Betaine anhydrous)
Limited evidenceNMN clearance via NNMT consumes methyl groups; TMG (trimethylglycine) is the conventional dietary methyl-group donor that replenishes them.
NMN is converted to NAD+ via NMNAT enzymes. The NAD+ salvage and clearance pathways consume S-adenosyl-methionine (SAM) for methylation reactions (notably nicotinamide N-methyltransferase, NNMT). High NAD+ flux therefore depletes the methyl pool. Trimethylglycine (TMG, also called betaine) is a direct methyl-group donor that regenerates methionine from homocysteine via betaine-homocysteine methyltransferase (BHMT), buffering the methyl pool against depletion. The pairing is widely cited in NAD-precursor stacks for this reason; the human-trial evidence for the combination as such is limited (mostly methylation-marker observational data, not clinical-outcome trials).
Evidence: Mechanistic biochemistry is well-described. Combination outcome trials in humans are sparse. Camden NB-161 includes both NMN (500 mg) and TMG (600 mg) at the commonly-cited literature ratio.
Doses studied: 500 mg NMN with 500–1,000 mg TMG daily (literature dose range)
Found in Camden: Clarifera™ NMN Complex 90 Delayed Release Capsules
Vitamin B12
Insufficient evidenceB12 is the regulatory anchor for any fatigue / energy framing on a multi-active NMN SKU — the EFSA-permitted claim attaches to B12, not to NMN.
Vitamin B12 (cobalamin) carries authorised EFSA health claims including reduction of tiredness and fatigue, normal energy- yielding metabolism, and normal psychological function. In a multi-active SKU containing NMN and B12, regulatory framing for energy / fatigue / cognition attaches to the B12, not to the NMN. This is a regulatory pairing, not a synergy claim.
Evidence: EFSA-authorised claims for B12 are settled regulatory positions. NMN itself has no authorised UK food-supplement health claims.
Doses studied: B12 100% NRV minimum to anchor a permitted claim; Camden NB-161 supplies 6,000% NRV at 150 µg methylcobalamin per capsule.
Found in Camden: Clarifera™ NMN Complex 90 Delayed Release Capsules
Resveratrol (trans-resveratrol)
Limited evidenceNMN and resveratrol both feature in NAD-pathway / sirtuin-activation stacks — the combination is a mechanistic stack, not an evidence-validated pairing.
Resveratrol has been studied as a putative SIRT1 activator; sirtuins are NAD+-dependent. The mechanistic stack pairs an NAD-precursor (NMN) with a sirtuin substrate (resveratrol). Human-trial outcomes for the combination are limited and the sirtuin-activation framing for resveratrol has been challenged by independent biochemistry. The pairing is convention rather than evidence-driven for outcome.
Evidence: Conventional in NAD-pathway stacks; outcome evidence is sparse. Camden NB-161 includes 170 mg trans-resveratrol per capsule.
Doses studied: NMN 250–500 mg with trans-resveratrol 100–250 mg daily.
Found in Camden: Clarifera™ NMN Complex 90 Delayed Release Capsules
NAD+ (Nicotinamide Adenine Dinucleotide)
Limited evidenceNAD+-precursor cluster — NAD+ end-product + NMN upstream precursor.
NMN (β-nicotinamide mononucleotide) is the direct NAD+ precursor via NMNAT pathway. NAD+ supplementation directly is poorly absorbed orally; NMN (or NR) is the more-absorbed route. Camden nmn NB-161 covers FSA novel-food regulatory-watch context.
Evidence: Camden nmn is the cluster reference.
Doses studied: Use NMN 250-1000 mg/day OR niacinamide 16 mg/day — NAD+ direct supplementation has poor oral bioavailability.
Pterostilbene (trans-pterostilbene)
Limited evidenceNAD+ + sirtuin cluster — NMN NAD+ precursor + pterostilbene sirtuin-activator framing.
NMN delivers NAD+ substrate; pterostilbene activates sirtuin-1 / sirtuin-3 (NAD+-dependent deacetylases). Mechanism complementary on sirtuin-activation axis. Camden NB-161 NMN Complex bundles both.
Evidence: Camden NB-161 cluster.
Doses studied: NMN 250-1000 mg + pterostilbene 50-100 mg daily.
Quercetin
Limited evidenceConventional in NAD-precursor stacks; quercetin contributes anti-inflammatory / flavonoid framing alongside NMN's NAD-precursor framing.
Quercetin and NMN target different pathways. Inclusion in NAD-precursor stacks is convention-driven. Outcome-trial evidence for the combination is sparse.
Evidence: Camden NB-161 supplies 300 mg quercetin + 500 mg NMN per capsule. NMN is on the FSA novel-food register as "pending"; this combination is discussed for mechanistic context.
Doses studied: Quercetin 250–500 mg + NMN 250–500 mg daily.
Vitamin B3 (Niacin / Nicotinamide)
Limited evidenceNAD+-precursor cluster — different precursor classes.
B3 nicotinamide salvage pathway → NAD+; NMN via NRK / NMNAT pathway → NAD+. Mechanism complementary.
Evidence: Camden nmn NB-161 covers FSA novel-food regulatory-watch context.
Doses studied: 16 mg B3 + 250-1000 mg NMN daily.